$9M for Syndax Pharmaceuticals

Xconomy Boston — 

Syndax Pharmaceuticals, a Waltham, MA-based developer of cancer therapies, has pulled in $9 million of a planned $16 million in a mixed offering of equity, options, and warrants, according to an SEC filing. Syndax’s past investors include Domain Associates and MPM Capital, which led a $40 million Series A round in 2007. The company launched in 2005 with intellectual property based on the work of Ronald Evans, a professor at San Diego’s Salk Institute for Biological Studies.